[
    [
        {
            "time": "2021-06-11",
            "original_text": "江苏区域股市周报：新增1家上市公司 63家机构调研前沿生物-U",
            "features": {
                "keywords": [
                    "江苏",
                    "上市公司",
                    "机构调研",
                    "前沿生物-U"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "江苏区域股市周报：新增1家上市公司 63家机构调研前沿生物-U",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-06-11",
            "original_text": "40亿大品种，恒瑞首仿上市",
            "features": {
                "keywords": [
                    "恒瑞",
                    "首仿",
                    "上市",
                    "40亿大品种"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "40亿大品种，恒瑞首仿上市",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-06-11",
            "original_text": "恒瑞PD-1获批一线鼻咽癌，次日市值损失116亿，为何？",
            "features": {
                "keywords": [
                    "恒瑞",
                    "PD-1",
                    "鼻咽癌",
                    "市值损失"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "恒瑞PD-1获批一线鼻咽癌，次日市值损失116亿，为何？",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-06-11",
            "original_text": "从云南白药看医药企业的投资选择",
            "features": {
                "keywords": [
                    "云南白药",
                    "医药企业",
                    "投资选择"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "从云南白药看医药企业的投资选择",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-06-11",
            "original_text": "揭秘送转股 132只除权以来股价上涨",
            "features": {
                "keywords": [
                    "送转股",
                    "股价上涨",
                    "除权"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "揭秘送转股 132只除权以来股价上涨",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-06-11",
            "original_text": "A股早报2021年6月11日星期五",
            "features": {
                "keywords": [
                    "A股",
                    "早报"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "A股早报2021年6月11日星期五",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 4
            }
        },
        {
            "time": "2021-06-10",
            "original_text": "A股融资融券日报：两融余额增加67.59亿元（6月10日）",
            "features": {
                "keywords": [
                    "A股",
                    "融资融券",
                    "两融余额",
                    "增加"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A股融资融券日报：两融余额增加67.59亿元（6月10日）",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 5,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-06-11",
            "original_text": "恒瑞首仿获批上市；卡瑞利珠单抗新适应症获批；百济神州开发细胞疗法；三部门部署2021医保工作",
            "features": {
                "keywords": [
                    "恒瑞",
                    "首仿",
                    "卡瑞利珠单抗",
                    "百济神州",
                    "细胞疗法",
                    "医保工作"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞首仿获批上市；卡瑞利珠单抗新适应症获批；百济神州开发细胞疗法；三部门部署2021医保工作",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]